WHO ICTRP trial
ZS-01-302 (Phsae III)
ChiCTR-TRC-10000992 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-TRC-10000992 |
|---|---|
| Public title | ZS-01-302 (Phsae III) |
| Scientific title | A Multi-center, Randomized, Double-blind, Placebo Parallel controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcuta |
| Primary sponsor | Cardiovascular Institute & Fuwai Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | Post-market |
| Countries | China |
| Conditions | Chronic Systolic Heart failure |
| Interventions | A:rhNRG-1 Subcutaneous Injection: 1.2ug/kg/day 8hours/day for 10days;B:rhNRG-1 Subcutaneous Injection: 0.6ug/kg/day 8hours/day for 10days;C:rhNRG-1 IV infusion, 0.6ug/kg/day 10hour/day, for 10days;D:placebo Subcutaneous Injection… |
| Registration date | Aug 6, 2010 |
| Target size | A:30;B:30;C:30;D:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: